Patents by Inventor Gurunadh Reddy Chichili

Gurunadh Reddy Chichili has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210155694
    Abstract: The present invention is directed to DA×CD3 Binding Molecules comprising a vCD3-Binding Domain, which comprises a CDRHI Domain, a CDRH2 Domain, a CDRH3 Domain, a CDRL I Domain, a CDRL2 Domain, and a CDRL3 Domain, at least one of which differs in amino acid sequence from the amino acid sequence of the corresponding CDR of a rCD3-Binding Domain, wherein the DA×CD3 Binding Molecule comprising such vCD3-Binding Domain exhibits an altered affinity for CD3, relative to a DA×CD3 Binding Molecule comprising such rCD3-Binding Domain. The invention particularly concerns to such DA×CD3 Binding Molecules comprising a vCD3-Binding Domain which exhibit reduced affinity for CD3 and are capable of mediating redirected killing of target cells expressing a DA and exhibit lower levels of cytokine release relative to a DA×CD3 Binding Molecule comprising a rCD3-Binding Domain.
    Type: Application
    Filed: February 13, 2019
    Publication date: May 27, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Ling Huang, Chia-Ying Kao Lam, Gurunadh Reddy Chichili, Ralph Froman Alderson, Paul A. Moore, Leslie S. Johnson
  • Publication number: 20210130470
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Application
    Filed: January 13, 2021
    Publication date: May 6, 2021
    Inventors: Leslie S. JOHNSON, Gurunadh Reddy CHICHILI, Kalpana SHAH, Ross LA MOTTE-MOHS, Paul A. Moore, Ezio Bonvini, Scott KOENIG
  • Patent number: 10954301
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: March 23, 2021
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20210047426
    Abstract: The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Application
    Filed: August 24, 2020
    Publication date: February 18, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Patent number: 10787521
    Abstract: The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: September 29, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Publication number: 20200207850
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Leslie S. JOHNSON, Ling HUANG, Gurunadh Reddy CHICHILI, Kalpana SHAH, Chia-Ying Kao LAM, Stephen James BURKE, Liqin LIU, Paul A. MOORE, Ezio BONVINI, Bhaswati BARAT
  • Patent number: 10647768
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 12, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
  • Publication number: 20190161548
    Abstract: The present invention is directed to bispecific molecules (e.g., diabodies, bispecific antibodies, trivalent binding molecules, etc.) that possess at least one epitope-binding site that is immunospecific for an epitope of PD-1 and at least one epitope-binding site that is immunospecific for an epitope of CTLA-4 (i.e., a “PD-1×CTLA-4 bispecific molecule”). The PD-1×CTLA-4 bispecific molecules of the present invention are capable of simultaneously binding to PD-1 and to CTLA-4, particularly as such molecules are arrayed on the surfaces of human cells. The invention is directed to pharmaceutical compositions that contain such PD-1×CTLA-4 bispecific molecules, and to methods involving the use of such bispecific molecules in the treatment of cancer and other diseases and conditions. The present invention also pertains to methods of using such PD-1×CTLA-4 bispecific molecules to stimulate an immune response.
    Type: Application
    Filed: December 12, 2016
    Publication date: May 30, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Gurunadh Reddy Chichili, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Ezio Bonvini, Scott Koenig
  • Publication number: 20190002563
    Abstract: The present invention is directed to B7-H3×CD3 bispecific monovalent diabodies, and particularly, to B7-H3×CD3 bispecific monovalent Fc diabodies, that are capable of simultaneous binding to B7-H3 and CD3. The invention is also directed to pharmaceutical compositions that contain such bispecific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.
    Type: Application
    Filed: August 12, 2016
    Publication date: January 3, 2019
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Ling Huang, Kalpana Shah, Ralph Alderson, Gurunadh Reddy Chichili
  • Publication number: 20180094072
    Abstract: The present invention is directed to sequence-optimized CD123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Application
    Filed: October 12, 2017
    Publication date: April 5, 2018
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Patent number: 9822181
    Abstract: The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: November 21, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson
  • Publication number: 20170198045
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multichain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Application
    Filed: May 29, 2015
    Publication date: July 13, 2017
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat